Clinical Trials on CAR T-Cell Therapy

Total 2145 results

Stiftung Swiss Tumor Institute
Klinik Hirslanden, Zurich; Palleos Healthcare GmbH

Recruiting

ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy (CARTePRO)

Patient Reported Outcome Measures | CAR T-Cell Therapy

Switzerland
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Recruiting

Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01) (CAR_21_01)

CAR-T Therapy Complications

Italy
Insel Gruppe AG, University Hospital Bern

Recruiting

Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy (IMCAR)

Vaccine Immunity in CAR-T Cell Therapy Recipients

Switzerland
Dartmouth-Hitchcock Medical Center

Completed

Patient Reported Outcomes and Patient Education in Cellular Therapy Patients

Lymphoma | Leukemia | Multiple Myeloma | Stem Cell Transplant | Hematopoietic Stem Cell Transplant | CAR T-Cell Therapy | HSCT | Cellular Therapy | CAR T-Cell Transplant

United States
Massachusetts General Hospital

Active, not recruiting

CAR T-CELL Therapy Educational Video Trial

Hematologic Malignancy | CAR-T Cell Therapy

United States
The Children's Hospital of Zhejiang University...
Chongqing Precision Biotech Co., Ltd

Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | CAR-T Cell Therapy

China
RenJi Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

CAR-T Cell Therapy

China
Tianjin Medical University Cancer Institute and...

Enrolling by invitation

AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

Peripheral T-cell Lymphoma Targeted Therapy

China
The Lymphoma Academic Research Organisation
Novartis; Gilead Sciences

Recruiting

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Hematopathology Eligible or CAR-t Cell Treatment

France
Shenzhen Fifth People's Hospital

Recruiting

An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects

CAR T-Cell Therapy

China
Center for International Blood and Marrow Transplant...

Recruiting

CIBMTR Research Database

Solid Tumors | Gene Therapy | Allogeneic Stem Cell Transplantation | Autologous Stem Cell Transplantation | Blood Cancers | Non-malignant Disease | CAR-T

United States
Second Affiliated Hospital of Soochow University
Soochow T-Maximun Biotechnology Co. LTD

Recruiting

Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma

Advanced Glioma | Complication of Chimeric Antigen Receptor (CAR-T) Cell Therapy

China
Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

Advanced Malignancies | PD-1 Antibody | CAR-T Cells

China
Shanghai International Medical Center

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

Advanced Solid Tumor | PD-1 Antibody | CAR-T Cells

China
University of Alabama at Birmingham

Terminated

Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T-cell Lymphomas | Adult T-cell Leukemia | Adult T-cell Lymphoma | Peripheral T-cell Lymphoma Unspecified | T/Null Cell Systemic Type | Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease

United States
Peking Union Medical College Hospital

Recruiting

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

Diffuse Large B Cell Lymphoma | Radiotherapy | CAR-T | Bridging Therapy

China
Myeloid Therapeutics

Suspended

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (IMAGINE)

Lymphoma, T-Cell, Cutaneous | Mycosis Fungoides | Lymphoma, T-Cell, Peripheral | Cell Therapy | Adoptive Cellular Immunotherapy

United States
Hebei Senlang Biotechnology Inc., Ltd.

Active, not recruiting

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

China
Second Affiliated Hospital of Guangzhou Medical...
Fapon Biotherapy Inc.

Recruiting

Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

Pancreas Cancer | Solid Tumor, Adult | CAR-T Cell Therapy | Mesothelin

China
National Cancer Institute (NCI)

Completed

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Peripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)

United States
National Cancer Institute (NCI)

Withdrawn

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

Hepatosplenic T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Extranodal NK-/T-cell Lymphoma, Nasal Type | Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma

United States
The First Affiliated Hospital of Soochow University

Recruiting

Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies

Hematological Malignancies | Chimeric Antigen Receptor T-cell Therapy

China
Memorial Sloan Kettering Cancer Center

Recruiting

Looking at Brain Changes in People With Lymphoma Receiving CAR-T Therapy

Lymphoma Receiving CAR-T Therapy

United States
Washington University School of Medicine
Wugen, Inc.

Recruiting

Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Acute Myeloid Leukemia | Sezary Syndrome | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult T Cell Leukemia | Adult T Cell Lymphoma | Hepatosplenic T-cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | T-Cell Non-Hodgkin... and other conditions

United States
Deepa Jagadeesh

Recruiting

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Enteropathy Associated T-cell Lymphoma | Hepato-splenic T-cell Lymphoma | NK T-cell Lymphoma

United States
Otsuka Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Japan
BeiGene

Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Cutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditions

China, Taiwan, Germany, France, Canada, Italy
University of Nebraska
National Cancer Institute (NCI); Amgen

Completed

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma

United States
SciTech Development, LLC
Rush University Medical Center

Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Mycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditions

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Suspended

Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies

Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | Anaplastic Lymphoma | Acute T Cell Leukemia | T-lymphoblastic Lymphoma

China
Legend Biotech USA Inc

Active, not recruiting

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

T-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma Recurrent

United States
Manchester University NHS Foundation Trust
University of Manchester; The Christie NHS Foundation Trust; Zenzium AI Ltd.; Aptus... and other collaborators

Recruiting

Enhanced Monitoring for Better Recovery and Cancer Experience in Greater Manchester (EMBRaCE-GM)

Colorectal Cancer | Lung Cancer | Hematological Cancer | CAR T-Cell Therapy

United Kingdom
Ohio State University Comprehensive Cancer Center
Celgene Corporation

Recruiting

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Cutaneous T-cell Lymphoma | Peripheral T-Cell Lymphoma | T-Prolymphocytic Leukemia | T-Large Granulocytic Leukemia | T-Lymphoblastic Leukemia/Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Cutaneous T-Cell Lymphoma | Peripheral T-Cell Lymphoma | Mature T-cell Malignancies | Relapsed/ Refractory T-cell Malignancies

United States
Autolus Limited

Enrolling by invitation

Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified

Multiple Myeloma | DLBCL | T Cell Lymphoma | Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy | ALL, Adult and Pediatric

United Kingdom
Samsung Medical Center
National Cancer Center, Korea; Asan Medical Center; Yonsei University; Korea Cancer...

Completed

RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas (RADCHOP)

Cutaneous T Cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-negative | Angioimmunoblastic T Cell Lymphoma | Peripheral T Cell Lymphoma Unspecified

Korea, Republic of
National Cancer Institute (NCI)

Completed

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Anaplastic Large Cell Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Adult Nasal Type Extranodal NK/T-Cell Lymphoma

United States, Canada
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Acute Myeloid Leukemia | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Extranodal NK/T-cell Lymphoma, Nasal Type | T-cell Prolymphocytic Leukemia | T-cell Large Granular Lymphocytic Leukemia | Peripheral T-cell Lymphoma, NOS | Enteropathy-type Intestinal T-cell Lymphoma

China
Celgene

Completed

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

Peripheral T-cell Lymphoma | Adult T-cell Leukemia-Lymphoma

Japan
Karyopharm Therapeutics Inc

Terminated

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)

Australia, Singapore
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co, Ltd. China

Unknown

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | NK/T-cell Lymphoma | Adult T-Cell Lymphoma/Leukaemia

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Registry for People With T-cell Lymphoma

Mycosis Fungoides | Sezary Syndrome | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | T-cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Primary Cutaneous Anaplastic Large... and other conditions

United States
Novartis Pharmaceuticals

Terminated

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

Leukemia-Lymphoma, Adult T-Cell | Cutaneous T-Cell Lymphoma

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL

Adult T-Cell Leukemia and Lymphoma (ATL) | Adult Peripheral T-Cell Lymphoma (PTCL)

Japan
University of Washington
National Cancer Institute (NCI)

Terminated

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

Cutaneous T-cell Lymphoma Stage I | Cutaneous T-cell Lymphoma Stage II | Cutaneous T-cell Lymphoma Stage III | Cutaneous T-cell Lymphoma Stage IV

United States
Singapore General Hospital

Completed

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Peripheral T-cell Lymphoma (Not Otherwise Specified) | Extranodal NK/T-cell Lymphoma Nasal Type | Enteropathy- Type T-cell Lymphoma | Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) | Relapsed ALCL (ALK-1 Positive) Post...

Singapore, Malaysia, Korea, Republic of
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Angioimmunoblastic T-cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma | Follicular T-Cell Lymphoma | Nodal Peripheral T-Cell Lymphoma...

United States
Dana-Farber Cancer Institute

Recruiting

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

Cutaneous T Cell Lymphoma | Peripheral T Cell Lymphoma

United States
Angimmune LLC
M.D. Anderson Cancer Center; Yale University; University of Texas Southwestern... and other collaborators

Completed

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

Mycosis Fungoides | Sezary Syndrome | T-cell Lymphomas | T-cell Leukemia | Cutaneous T-cell Lymphoma (CTCL)

United States
Daiichi Sankyo

Active, not recruiting

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Relapsed/Refractory Peripheral T-Cell Lymphoma | Adult T Cell Leukemia/Lymphoma

United States, Spain, Japan, United Kingdom, Korea, Republic of, France, Italy, Australia, Canada, Germany, Netherlands, Taiwan

Clinical Trials on CAR T-Cell Therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations